Skip to main content

REDES TRANSCRIPCIONALES Y DIFERENCIACION LUMINAL EN LA METASTASIS DEL CANCER DE MAMA: UNA APROXIMACION BIOLOGICA PARA TRATAMIENTOS EFECTIVOS

PID2019-104948RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT DE RECERCA BIOMEDICA (BARCELONA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer

  • Pérez-Núñez, Iván
  • Rozalén, Catalina
  • Palomeque, José Ángel
  • Sangrador, Irene
  • Dalmau, Mariona
  • Comerma Blesa, Laura, 1983-
  • Hernández Prat, Anna, 1984-
  • Casadevall Aguilar, David
  • Menendez Romero, Silvia
  • Liu, Dan
  • Berenguer De Felipe, Jordi
  • Peña Arranz, Raúl, 1976-
  • Montañés, José Carlos
  • Albà Soler, Mar
  • Bonnin, Sarah
  • Ponomarenko, Julia
  • Servitja Tormo, Sonia
  • Arribas, Joaquín
  • Albanell Mestres, Joan
  • Celià-Terrassa, Toni
Ligand-dependent corepressor (LCOR) mediates normal and malignant breast stem cell differentiation. Cancer stem cells (CSCs) generate phenotypic heterogeneity and drive therapy resistance, yet their role in immunotherapy is poorly understood. Here we show that immune-checkpoint blockade (ICB) therapy selects for LCORlow CSCs with reduced antigen processing/presentation machinery (APM) driving immune escape and ICB resistance in triple-negative breast cancer (TNBC). We unveil an unexpected function of LCOR as a master transcriptional activator of APM genes binding to IFN-stimulated response elements (ISREs) in an IFN signaling-independent manner. Through genetic modification of LCOR expression, we demonstrate its central role in modulation of tumor immunogenicity and ICB responsiveness. In TNBC, LCOR associates with ICB clinical response. Importantly, extracellular vesicle (EV) Lcor-messenger RNA therapy in combination with anti-PD-L1 overcame resistance and eradicated breast cancer metastasis in preclinical models. Collectively, these data support LCOR as a promising target for enhancement of ICB efficacy in TNBC, by boosting of tumor APM independently of IFN., This work was supported by the Instituto de Salud Carlos III-FSE (nos. MS17/00037 and PI18/00014) and the Cancer Research Institute, Clinic and Laboratory Integration Program (grant no. CRI2477 to T.C.-T). We also thank the AECC LAB (grant no. LABAE19007CELI) and the FERO foundation (to T.C.-T). This work was also supported by ISCIII (CIBERONC nos. CB16/12/00481, CB16/12/00241, PI18/00006 and PI21/00002), Generalitat de Catalunya (no. 2017 SGR 507) and the European Community through the Regional Development Funding Program to J. Albanell. Y.K. is supported by the Brewster Foundation, the Breast Cancer Research Foundation, the Susan G. Komen Foundation and the American Cancer Society. J. Arribas is funded by the Breast Cancer Research Foundation (no. BCRF-20-08), Instituto de Salud Carlos III (no. PI19/01181), Asociación Española Contra el Cáncer (no. GCAEC19017ARRI) and Fundación BBVA (no. CAIMI VHIO-FBBVA 2018-2021). M.M.A. is funded by MICINN and the Spanish Government (no. PGC2018-094091-B-I00). D.C. was funded by Instituto de Salud Carlos III (no. JR1800003). S.M. is funded by PERIS (no. SLT006/17/00040). The wotk of R.R.G. is funded by MICINN, the Spanish Government (no. PID2019-104948RB-I00) and the BBVA Foundation. S.B and J.P. acknowledge support from the Spanish Ministry of Science, the EMBL partnership and the CESO and CERCA Program.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy

  • Linares Aceituno, Jenniffer Lissethe
  • Sallent-Aragay, Anna
  • Badia-Ramentol, Jordi
  • Recort-Bascuas, Alba
  • Manero Rupérez, Noemí
  • Rivas, Elisa
  • Zwick, Melissa
  • Iglesias Coma, Mar
  • Orrillo, Mayra
  • Garrido, Marta
  • Navarro Medrano, Pilar
  • Montagut Viladot, Clara
  • Calon, Alexandre
A substantial proportion of cancer patients do not benefit from platinum-based chemotherapy (CT) due to the emergence of drug resistance. Here, we apply elemental imaging to the mapping of CT biodistribution after therapy in residual colorectal cancer and achieve a comprehensive analysis of the genetic program induced by oxaliplatin-based CT in the tumor microenvironment. We show that oxaliplatin is largely retained by cancer-associated fibroblasts (CAFs) long time after the treatment ceased. We determine that CT accumulation in CAFs intensifies TGF-beta activity, leading to the production of multiple factors enhancing cancer aggressiveness. We establish periostin as a stromal marker of chemotherapeutic activity intrinsically upregulated in consensus molecular subtype 4 (CMS4) tumors and highly expressed before and/or after treatment in patients unresponsive to therapy. Collectively, our study underscores the ability of CT-retaining CAFs to support cancer progression and resistance to treatment., This work has been supported by grants from Fundación científica AECC -Asociación Española contra el Cáncer- (GCAEC20030CERV) to A.Ce., from Instituto de Salud Carlos III (ISCIII) co-funded by the European Union (CP16/00151, PI17/00211, PI20/00011; Spanish Ministry of Economy and Competitiveness) to A.Ca. and PI20/00625 to P.N., from la Caixa Foundation (LCF/PR/HR19/52160018) and MICINN (PID2020-119917RB-I00) to E.B., from Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds (PID2019-104948RB-I00) to R.R.G. This work was supported by Grant PT20/00023, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and the Xarxa de Bancs de tumors sponsored by Pla Director d’Oncologia de Catalunya (XBTC). A.Ca. is the recipient of funding from the Instituto de Salud Carlos III co-funded by the European Union (MS16/00151; CPII21/00012). J.L. is the recipient of a Junior Clinician fellowship from Fundación científica AECC (CLJUN19004LINA).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis

  • Llorente, Alicia
  • Ballaré, Cecilia Julia
  • Blanco, Enrique
  • Di Croce, Luciano
  • Gomis, Roger R.
MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms that are still poorly understood yet have important clinical implications. Oestrogen-receptor-positive (ER+) BCa requires oestrogen for both growth and metastasis, albeit by ill-known mechanisms. Here we integrate proteomics, transcriptomics, epigenomics, chromatin accessibility and functional assays from human and syngeneic mouse BCa models to show that MAF directly interacts with oestrogen receptor alpha (ERα), thereby promoting a unique chromatin landscape that favours metastatic spread. We identify metastasis-promoting genes that are de novo licensed following oestrogen exposure in a MAF-dependent manner. The histone demethylase KDM1A is key to the epigenomic remodelling that facilitates the expression of the pro-metastatic MAF/oestrogen-driven gene expression program, and loss of KDM1A activity prevents this metastasis. We have thus determined that the molecular basis underlying MAF/oestrogen-mediated metastasis requires genetic, epigenetic and hormone signals from the systemic environment, which influence the ability of BCa cells to metastasize., We also thank V. Raker for her editing support. A.L. and I.E. are supported by FPI-SO grants and A.B. and C.F.-P. by FPI Fellowship grants from Gobierno de España. M.F. is supported by the Horizon 2020 Research and Innovation Programme under Marie Skłodowska–Curie grant agreement no. 955951; M.T.B. is supported by an AECC (Spanish Cancer Association) postdoctoral grant, M.N. and R.R.G. by an AECC grant Proyecto GCTRA18006CARR. R.R.G. and L.D.C. are supported by the Institució Catalana de Recerca i Estudis Avançats. Special thanks go to Carme Segura Capellades for generously supporting our endeavours. Support and structural funds were provided by the Generalitat de Catalunya (2021-SGR-00909) to R.R.G., and by the BBVA Foundation, Fundación Científica AECC (PRYGN223207GOMI), the ISCIII/FEDER-CIBERONC, the ‘la Caixa’ Foundation (ID 100010434) under agreement HR17-00092, the FERO Foundation, the Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds (CIBERONC and PID2019-104948RB-I00; PID2022-143093OB-100) to R.R.G. Work in the L.D.C. laboratory is supported by grants from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (PID2019-108322GB-100) and from AGAUR. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy

  • Linares, Jenniffer
  • Sallent-Aragay, Anna
  • Badia-Ramentol, Jordi
  • Recort-Bascuas, Alba
  • Méndez, Ana
  • Manero-Rupérez, Noemí
  • Re, Daniele Lo
  • Rivas, Elisa I.
  • Guiu, Marc
  • Zwick, Melissa
  • Iglesias, Mar
  • Martinez-Ciarpaglini, Carolina
  • Tarazona, Noelia
  • Varese, Monica
  • Hernando-Momblona, Xavier
  • Cañellas-Socias, Adrià
  • Orriols, Mayra
  • Garrido, Marta
  • Saoudi, Nadia
  • Élez, Elena
  • Navarro Medrano, Pilar
  • Tabernero, Josep
  • Gomis, Roger R.
  • Batlle, Eduard
  • Pisonero, Jorge
  • Cervantes, Andrés
  • Montagut, Clara
  • Calon, Alexandre
A substantial proportion of cancer patients do not benefit from platinum-based chemotherapy (CT) due to the emergence of drug resistance. Here, we apply elemental imaging to the mapping of CT biodistribution after therapy in residual colorectal cancer and achieve a comprehensive analysis of the genetic program induced by oxaliplatin-based CT in the tumor microenvironment. We show that oxaliplatin is largely retained by cancer-associated fibroblasts (CAFs) long time after the treatment ceased. We determine that CT accumulation in CAFs intensifies TGF-beta activity, leading to the production of multiple factors enhancing cancer aggressiveness. We establish periostin as a stromal marker of chemotherapeutic activity intrinsically upregulated in consensus molecular subtype 4 (CMS4) tumors and highly expressed before and/or after treatment in patients unresponsive to therapy. Collectively, our study underscores the ability of CT-retaining CAFs to support cancer progression and resistance to treatment., This work has been supported by grants from Fundación científica AECC -Asociación Española contra el Cáncer- (GCAEC20030CERV) to A.Ce., from Instituto de Salud Carlos III (ISCIII) co-funded by the European Union (CP16/00151, PI17/00211, PI20/00011; Spanish Ministry of Economy and Competitiveness) to A.Ca. and PI20/00625 to P.N., from la Caixa Foundation (LCF/PR/HR19/52160018) and MICINN (PID2020- 119917RB-I00) to E.B., from Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds (PID2019-104948RB-I00) to R.R.G. This work was supported by Grant PT20/00023, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and the Xarxa de Bancs de tumors sponsored by Pla Director d’Oncologia de Catalunya (XBTC). A.Ca. is the recipient of funding from the Instituto de Salud Carlos III co-funded by the European Union (MS16/00151; CPII21/00012). J.L. is the recipient of a Junior Clinician fellowship from Fundación científica AECC (CLJUN19004LINA).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer

  • Pérez-Núñez, Iván
  • Rozalén, Catalina
  • Palomeque, José Ángel
  • Sangrador, Irene
  • Dalmau, Mariona
  • Comerma Blesa, Laura, 1983-
  • Hernández Prat, Anna, 1984-
  • Casadevall Aguilar, David
  • Menendez Romero, Silvia
  • Liu, Dan
  • Berenguer De Felipe, Jordi
  • Peña Arranz, Raúl, 1976-
  • Montañés, José Carlos
  • Albà Soler, Mar
  • Bonnin, Sarah
  • Ponomarenko, Julia
  • Servitja Tormo, Sonia
  • Arribas, Joaquín
  • Albanell Mestres, Joan
  • Celià-Terrassa, Toni
Ligand-dependent corepressor (LCOR) mediates normal and malignant breast stem cell differentiation. Cancer stem cells (CSCs) generate phenotypic heterogeneity and drive therapy resistance, yet their role in immunotherapy is poorly understood. Here we show that immune-checkpoint blockade (ICB) therapy selects for LCORlow CSCs with reduced antigen processing/presentation machinery (APM) driving immune escape and ICB resistance in triple-negative breast cancer (TNBC). We unveil an unexpected function of LCOR as a master transcriptional activator of APM genes binding to IFN-stimulated response elements (ISREs) in an IFN signaling-independent manner. Through genetic modification of LCOR expression, we demonstrate its central role in modulation of tumor immunogenicity and ICB responsiveness. In TNBC, LCOR associates with ICB clinical response. Importantly, extracellular vesicle (EV) Lcor-messenger RNA therapy in combination with anti-PD-L1 overcame resistance and eradicated breast cancer metastasis in preclinical models. Collectively, these data support LCOR as a promising target for enhancement of ICB efficacy in TNBC, by boosting of tumor APM independently of IFN., This work was supported by the Instituto de Salud Carlos III-FSE (nos. MS17/00037 and PI18/00014) and the Cancer Research Institute, Clinic and Laboratory Integration Program (grant no. CRI2477 to T.C.-T). We also thank the AECC LAB (grant no. LABAE19007CELI) and the FERO foundation (to T.C.-T). This work was also supported by ISCIII (CIBERONC nos. CB16/12/00481, CB16/12/00241, PI18/00006 and PI21/00002), Generalitat de Catalunya (no. 2017 SGR 507) and the European Community through the Regional Development Funding Program to J. Albanell. Y.K. is supported by the Brewster Foundation, the Breast Cancer Research Foundation, the Susan G. Komen Foundation and the American Cancer Society. J. Arribas is funded by the Breast Cancer Research Foundation (no. BCRF-20-08), Instituto de Salud Carlos III (no. PI19/01181), Asociación Española Contra el Cáncer (no. GCAEC19017ARRI) and Fundación BBVA (no. CAIMI VHIO-FBBVA 2018-2021). M.M.A. is funded by MICINN and the Spanish Government (no. PGC2018-094091-B-I00). D.C. was funded by Instituto de Salud Carlos III (no. JR1800003). S.M. is funded by PERIS (no. SLT006/17/00040). The wotk of R.R.G. is funded by MICINN, the Spanish Government (no. PID2019-104948RB-I00) and the BBVA Foundation. S.B and J.P. acknowledge support from the Spanish Ministry of Science, the EMBL partnership and the CESO and CERCA Program.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis

  • Llorente, Alicia
  • Ballaré, Cecilia Julia
  • Blanco, Enrique
  • Di Croce, Luciano
  • Gomis, Roger R.
MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms that are still poorly understood yet have important clinical implications. Oestrogen-receptor-positive (ER+) BCa requires oestrogen for both growth and metastasis, albeit by ill-known mechanisms. Here we integrate proteomics, transcriptomics, epigenomics, chromatin accessibility and functional assays from human and syngeneic mouse BCa models to show that MAF directly interacts with oestrogen receptor alpha (ERα), thereby promoting a unique chromatin landscape that favours metastatic spread. We identify metastasis-promoting genes that are de novo licensed following oestrogen exposure in a MAF-dependent manner. The histone demethylase KDM1A is key to the epigenomic remodelling that facilitates the expression of the pro-metastatic MAF/oestrogen-driven gene expression program, and loss of KDM1A activity prevents this metastasis. We have thus determined that the molecular basis underlying MAF/oestrogen-mediated metastasis requires genetic, epigenetic and hormone signals from the systemic environment, which influence the ability of BCa cells to metastasize., We also thank V. Raker for her editing support. A.L. and I.E. are supported by FPI-SO grants and A.B. and C.F.-P. by FPI Fellowship grants from Gobierno de España. M.F. is supported by the Horizon 2020 Research and Innovation Programme under Marie Skłodowska–Curie grant agreement no. 955951; M.T.B. is supported by an AECC (Spanish Cancer Association) postdoctoral grant, M.N. and R.R.G. by an AECC grant Proyecto GCTRA18006CARR. R.R.G. and L.D.C. are supported by the Institució Catalana de Recerca i Estudis Avançats. Special thanks go to Carme Segura Capellades for generously supporting our endeavours. Support and structural funds were provided by the Generalitat de Catalunya (2021-SGR-00909) to R.R.G., and by the BBVA Foundation, Fundación Científica AECC (PRYGN223207GOMI), the ISCIII/FEDER-CIBERONC, the ‘la Caixa’ Foundation (ID 100010434) under agreement HR17-00092, the FERO Foundation, the Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds (CIBERONC and PID2019-104948RB-I00; PID2022-143093OB-100) to R.R.G. Work in the L.D.C. laboratory is supported by grants from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (PID2019-108322GB-100) and from AGAUR. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy

  • Linares Aceituno, Jenniffer Lissethe
  • Sallent-Aragay, Anna
  • Badia-Ramentol, Jordi
  • Recort-Bascuas, Alba
  • Manero Rupérez, Noemí
  • Rivas, Elisa
  • Zwick, Melissa
  • Iglesias Coma, Mar
  • Orrillo, Mayra
  • Garrido, Marta
  • Navarro Medrano, Pilar
  • Montagut Viladot, Clara
  • Calon, Alexandre
A substantial proportion of cancer patients do not benefit from platinum-based chemotherapy (CT) due to the emergence of drug resistance. Here, we apply elemental imaging to the mapping of CT biodistribution after therapy in residual colorectal cancer and achieve a comprehensive analysis of the genetic program induced by oxaliplatin-based CT in the tumor microenvironment. We show that oxaliplatin is largely retained by cancer-associated fibroblasts (CAFs) long time after the treatment ceased. We determine that CT accumulation in CAFs intensifies TGF-beta activity, leading to the production of multiple factors enhancing cancer aggressiveness. We establish periostin as a stromal marker of chemotherapeutic activity intrinsically upregulated in consensus molecular subtype 4 (CMS4) tumors and highly expressed before and/or after treatment in patients unresponsive to therapy. Collectively, our study underscores the ability of CT-retaining CAFs to support cancer progression and resistance to treatment., This work has been supported by grants from Fundación científica AECC -Asociación Española contra el Cáncer- (GCAEC20030CERV) to A.Ce., from Instituto de Salud Carlos III (ISCIII) co-funded by the European Union (CP16/00151, PI17/00211, PI20/00011; Spanish Ministry of Economy and Competitiveness) to A.Ca. and PI20/00625 to P.N., from la Caixa Foundation (LCF/PR/HR19/52160018) and MICINN (PID2020-119917RB-I00) to E.B., from Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds (PID2019-104948RB-I00) to R.R.G. This work was supported by Grant PT20/00023, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, and the Xarxa de Bancs de tumors sponsored by Pla Director d’Oncologia de Catalunya (XBTC). A.Ca. is the recipient of funding from the Instituto de Salud Carlos III co-funded by the European Union (MS16/00151; CPII21/00012). J.L. is the recipient of a Junior Clinician fellowship from Fundación científica AECC (CLJUN19004LINA).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis

  • Llorente, Alicia
  • Blasco, María Teresa
  • Espuny, Irene|||0000-0003-1906-4947
  • Guiu, Marc|||0000-0002-7083-986X
  • Ballaré, Cecilia
  • Blanco, Enrique|||0000-0001-6261-7370
  • Caballé Mestres, Adrià|||0000-0002-2388-4713
  • Bellmunt, Anna|||0000-0002-4810-3848
  • Salvador, Fernando|||0000-0002-0546-1354
  • Morales, Andrea
  • Nuñez, Marc
  • Loren, Guillem
  • Imbastari, Francesca
  • Fidalgo, Marta
  • Figueras-Puig, Cristina|||0000-0003-4457-6864
  • Gibler, Patrizia|||0000-0003-4100-4318
  • Graupera, Mariona|||0000-0003-4608-4185
  • Monteiro, Freddy|||0000-0002-9080-6715
  • Riera, Antoni|||0000-0001-7142-7675
  • Holen, Ingunn|||0000-0002-8759-6913
  • Avgustinova, Alexandra
  • Di Croce, Luciano|||0000-0003-3488-6228
  • Gomis, Roger R..|||0000-0001-6473-2858
MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms that are still poorly understood yet have important clinical implications. Oestrogen-receptor-positive (ER) BCa requires oestrogen for both growth and metastasis, albeit by ill-known mechanisms. Here we integrate proteomics, transcriptomics, epigenomics, chromatin accessibility and functional assays from human and syngeneic mouse BCa models to show that MAF directly interacts with oestrogen receptor alpha (ERα), thereby promoting a unique chromatin landscape that favours metastatic spread. We identify metastasis-promoting genes that are de novo licensed following oestrogen exposure in a MAF-dependent manner. The histone demethylase KDM1A is key to the epigenomic remodelling that facilitates the expression of the pro-metastatic MAF/oestrogen-driven gene expression program, and loss of KDM1A activity prevents this metastasis. We have thus determined that the molecular basis underlying MAF/oestrogen-mediated metastasis requires genetic, epigenetic and hormone signals from the systemic environment, which influence the ability of BCa cells to metastasize.